Results 81 to 90 of about 85,285 (279)
Metabolic changes in immune cells direct the phenotype and function of the host immune system. Smart nanomaterials must target metabolic pathways to direct immune cell fate. This study reports the fabrication and first application of germanane quantum dots (GeHQDs) to modulate inflammation in vitro and in vivo.
Abhay Srivastava +7 more
wiley +1 more source
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
<b><i>Background:</i></b> With recent developments in diabetes technology, attaining adequate glucose control is more achievable than ever. Despite these improvements, a significant proportion of individuals with type 1 diabetes do not reach recommended glycaemic goals.
Tim Hropot, Tadej Battelino, Klemen Dovc
openaire +3 more sources
Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis [PDF]
Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are a novel drug class for the treatment of diabetes. We aimed at describing the maximal benefits and risks associated with SGLT2-i for patients with type 2 diabetes.Systematic review and meta-analysis.
A Berhan +103 more
core +3 more sources
Liquid crystalline inverted lipid phases and reverse micelles are self‐assembled lipid nanostructures that enhance the solubility, stability, and delivery of diverse therapeutics. This review integrates their physicochemical principles, formulation strategies, drug loading mechanisms, and biomedical applications, highlighting their growing ...
Numan Eczacioglu +3 more
wiley +1 more source
Sodium-glucose co-transporter type 2 inhibitors belong to modern class of oral hypoglycemic drugs, exerting its effect through the reduction of renal glucose reabsorption.
D. A. Lebedev +4 more
doaj
Canagliflozin: A Review in Type 2 Diabetes. [PDF]
peer reviewedCanagliflozin (Invokana(R)) is a sodium-glucose co-transporter-2 (SGLT2) inhibitor indicated in various countries worldwide for the once-daily oral treatment of type 2 diabetes (T2D).
Deeks, Emma D., Scheen, André
core +2 more sources
A UV‐triggered injectable dual‐network hydrogel is reported as the first application of bletilla striata polysaccharide (BSP) in osteochondral repair. By integrating methacrylamide‐modified BSP and nitrobenzaldehyde‐functionalized hyaluronic acid, the system achieves immunomodulation, mechanical reinforcement, and dynamic tissue adhesion, thereby ...
Jiaming Cui +10 more
wiley +1 more source
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
Sotagliflozin is a dual sodium–glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium–glucose co-transporter 2 (determining significant excretion of glucose
Chiara Maria Assunta Cefalo +7 more
doaj +1 more source
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
peer ...
Mifsud, Simon +3 more
openaire +1 more source
Organic Cation Transporter 3: A Cellular Mechanism Underlying Rapid, Non-Genomic Glucocorticoid Regulation of Monoaminergic Neurotransmission, Physiology, and Behavior [PDF]
Corticosteroid hormones act at intracellular glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) to alter gene expression, leading to diverse physiological and behavioral responses.
Gasser, Paul J., Lowry, Christopher A.
core +2 more sources

